How should I manage a patient with serum creatinine 1.69 mg/dL, estimated glomerular filtration rate 28 mL/min/1.73 m², and urine albumin‑creatinine ratio 1,158 mg/g?

Management of Stage 4 CKD with Severe Albuminuria

Immediate Diagnostic Confirmation and Risk Stratification

This patient has Stage 4 chronic kidney disease (eGFR 28 mL/min/1.73 m²) with severely elevated albuminuria (UACR 1,158 mg/g), placing them at very high risk for both kidney failure and cardiovascular events—immediate nephrology referral and initiation of nephroprotective therapy are mandatory. 1, 2

• Confirm CKD chronicity by repeating serum creatinine in 2–4 weeks to exclude acute kidney injury superimposed on chronic disease 1
• Obtain two additional first-morning urine albumin-to-creatinine ratio measurements over the next 3–6 months to confirm persistent severe albuminuria (UACR >300 mg/g defines severely increased albuminuria) 3, 1
• Calculate eGFR using the 2021 CKD-EPI equation without race adjustment rather than relying on serum creatinine alone, as creatinine markedly underestimates renal impairment 3, 4

Nephrology Referral—Urgent and Non-Negotiable

Refer to nephrology immediately because this patient meets multiple high-risk criteria 1, 2:

• UACR ≥300 mg/g (this patient has 1,158 mg/g—nearly four times the threshold)
• eGFR <30 mL/min/1.73 m² (Stage 4 CKD)
• High likelihood of rapid progression requiring preparation for kidney replacement therapy

Nephroprotective Medication Algorithm

Step 1: ACE Inhibitor or ARB Initiation

Start an ACE inhibitor or ARB immediately if not already prescribed, even if blood pressure is normal, because UACR ≥30 mg/g mandates renin-angiotensin system blockade for blood-pressure-independent nephroprotection 1, 2

• Target systolic blood pressure <130 mmHg (but not <120 mmHg) 1
• Re-check serum creatinine and potassium 2–4 weeks after initiation or dose escalation 1
• Continue the ACE inhibitor/ARB unless creatinine rises >30% within 4 weeks; smaller increases (up to 30%) are expected hemodynamic changes and should not trigger discontinuation 1, 2
• Manage hyperkalemia with dietary potassium restriction or potassium binders rather than stopping the RAS blocker 1

Step 2: SGLT2 Inhibitor—Highest Priority Addition

Initiate an SGLT2 inhibitor (empagliflozin, canagliflozin, or dapagliflozin) immediately because this patient has UACR ≥200 mg/g and eGFR ≥20 mL/min/1.73 m² 1, 2

• SGLT2 inhibitors reduce CKD progression and cardiovascular events with Level 1A evidence 1
• In the DAPA-CKD trial, dapagliflozin reduced the composite endpoint of ≥50% sustained eGFR decline, progression to end-stage kidney disease, or cardiovascular/renal death by 39% (HR 0.61,95% CI 0.51–0.72, p<0.0001) in patients with mean baseline eGFR 43 mL/min/1.73 m² and median UACR 950 mg/g—nearly identical to this patient's profile 5
• Continue the SGLT2 inhibitor even if eGFR falls below 20 mL/min/1.73 m² unless the drug is not tolerated or the patient initiates dialysis 1
• An initial reversible eGFR decline of 2–3 mL/min/1.73 m² within the first 2 weeks is expected and does not require discontinuation 1

Step 3: Consider Non-Steroidal Mineralocorticoid Receptor Antagonist

• If albuminuria persists despite maximally tolerated ACE inhibitor/ARB and SGLT2 inhibitor, consider adding finerenone if eGFR >25 mL/min/1.73 m² and potassium is normal 1

Baseline Laboratory Assessment of CKD Complications

Obtain baseline serum potassium, hemoglobin, calcium, phosphate, and bicarbonate to screen for CKD-related complications that become common when eGFR falls below 60 mL/min/1.73 m² 1

• Monitor hemoglobin, calcium, phosphate, and bicarbonate every 6–12 months to identify anemia, mineral-bone disorder, and metabolic acidosis 1
• Perform periodic serum potassium checks in patients receiving ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists 1

Medication Safety and Nephrotoxin Avoidance

Review and adjust doses of all renally cleared medications because many require modification when eGFR is <60 mL/min/1.73 m² 1

• Calculate creatinine clearance using the Cockcroft-Gault formula for medication dosing decisions, not the eGFR value 4
• Avoid NSAIDs entirely—the "triple whammy" (NSAID + ACE inhibitor/ARB + diuretic) markedly increases acute kidney injury risk 1
• Minimize exposure to iodinated contrast agents and other nephrotoxic substances 1

Cardiovascular Risk Management

Initiate statin therapy because the majority of CKD patients have a 10-year ASCVD risk ≥10%, placing them in the high-risk category 1

• Statins do not require dose adjustment at eGFR 28 mL/min/1.73 m² 1
• Screen for diabetes via HbA1c, as approximately 27% of hypertensive patients have diabetes 1
• Address smoking cessation if applicable 1

Monitoring Schedule

Schedule clinic visits every 6–8 weeks until blood pressure goal is achieved 1

• After reaching target BP, perform laboratory monitoring (creatinine, eGFR, UACR, potassium) and clinic follow-up every 3–6 months 1
• Assess eGFR and albuminuria at least every 3 months given the high risk of progression 1

Critical Pitfalls to Avoid

• Do not discontinue ACE inhibitor/ARB for creatinine rises <30% unless there is clear volume depletion; stopping eliminates nephroprotection 1
• Do not stop an SGLT2 inhibitor because of the expected initial eGFR dip of 2–3 mL/min/1.73 m² 1
• Never use serum creatinine alone to assess kidney function; always calculate eGFR using the CKD-EPI equation 3, 4
• Educate the patient on "sick-day rules": temporarily hold ACE inhibitor/ARB, diuretics, and SGLT2 inhibitors during acute illnesses with volume depletion (vomiting, diarrhea, fever) 1
• Withhold SGLT2 inhibitors during prolonged fasting, surgery, or critical illness due to the risk of ketoacidosis 5

Preparation for Kidney Replacement Therapy

Begin discussing kidney replacement therapy options (hemodialysis, peritoneal dialysis, kidney transplantation) because eGFR 28 mL/min/1.73 m² is approaching Stage 5 CKD (eGFR <15 mL/min/1.73 m²) 1

• Consider vascular access planning (arteriovenous fistula creation) if hemodialysis is anticipated, as fistulas require 3–6 months to mature 1
• Evaluate for kidney transplantation candidacy early, as the evaluation process is lengthy 1